Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer : Updated Analysis of the RESET Study
PURPOSE: This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced-stage epidermal growth factor receptor (EGFR)+ non-small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with other second-line regimens (comparator group).
MATERIALS AND METHODS: In this updated report, the existing medical records were reviewed and rechecked. TOT and OS were updated and analyzed according to clinical features using the Kaplan-Meier method and log-rank test. TOT and OS were compared with those of the comparator group, in which most patients received pemetrexed-based treatments. A multivariable Cox proportional hazard model was used to evaluate features that could affect survival outcomes.
RESULTS: The median observation time was 31.0 months. The follow-up period was extended to 20 months. A total of 401 patients who received first-line afatinib were analyzed (166 with T790M+ and second-line osimertinib, and 235 with unproven T790M and other second-line agents). Median TOTs on afatinib and osimertinib were 15.0 months (95% confidence interval [CI], 14.0 to 16.1) and 11.9 months (95% CI, 8.9 to 14.6), respectively. The median OS in the osimertinib group was 54.3 months (95% CI, 46.7 to 61.9), much longer than that in the comparator group. In patients who received osimertinib, the OS was longest with Del19+ (median, 59.1; 95% CI, 48.7 to 69.5).
CONCLUSION: This is one of the largest real-world studies reporting the encouraging activity of sequential afatinib and osimertinib in Asian patients with EGFR+ NSCLC who acquired the T790M mutation, particularly Del19+.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Cancer research and treatment - 55(2023), 4 vom: 23. Okt., Seite 1152-1170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Taeyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3C06JJ0Z2O |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4143/crt.2023.493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357205928 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357205928 | ||
| 003 | DE-627 | ||
| 005 | 20231226072103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4143/crt.2023.493 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357205928 | ||
| 035 | |a (NLM)37218139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Taeyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer |b Updated Analysis of the RESET Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced-stage epidermal growth factor receptor (EGFR)+ non-small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with other second-line regimens (comparator group) | ||
| 520 | |a MATERIALS AND METHODS: In this updated report, the existing medical records were reviewed and rechecked. TOT and OS were updated and analyzed according to clinical features using the Kaplan-Meier method and log-rank test. TOT and OS were compared with those of the comparator group, in which most patients received pemetrexed-based treatments. A multivariable Cox proportional hazard model was used to evaluate features that could affect survival outcomes | ||
| 520 | |a RESULTS: The median observation time was 31.0 months. The follow-up period was extended to 20 months. A total of 401 patients who received first-line afatinib were analyzed (166 with T790M+ and second-line osimertinib, and 235 with unproven T790M and other second-line agents). Median TOTs on afatinib and osimertinib were 15.0 months (95% confidence interval [CI], 14.0 to 16.1) and 11.9 months (95% CI, 8.9 to 14.6), respectively. The median OS in the osimertinib group was 54.3 months (95% CI, 46.7 to 61.9), much longer than that in the comparator group. In patients who received osimertinib, the OS was longest with Del19+ (median, 59.1; 95% CI, 48.7 to 69.5) | ||
| 520 | |a CONCLUSION: This is one of the largest real-world studies reporting the encouraging activity of sequential afatinib and osimertinib in Asian patients with EGFR+ NSCLC who acquired the T790M mutation, particularly Del19+ | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Afatinib | |
| 650 | 4 | |a ErbB receptors | |
| 650 | 4 | |a Non–small-cell lung carcinoma | |
| 650 | 4 | |a Osimertinib | |
| 650 | 4 | |a Real-world effectiveness | |
| 650 | 7 | |a Afatinib |2 NLM | |
| 650 | 7 | |a 41UD74L59M |2 NLM | |
| 650 | 7 | |a osimertinib |2 NLM | |
| 650 | 7 | |a 3C06JJ0Z2O |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Jang, Tae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Chang Min |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Mi-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yoon Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kye Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Joon |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Sei Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Jeong Seon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeong Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Shin Yup |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Chan Kwon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Seung Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Seong Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Hyung-Joo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research and treatment |d 2001 |g 55(2023), 4 vom: 23. Okt., Seite 1152-1170 |w (DE-627)NLM190743158 |x 2005-9256 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:4 |g day:23 |g month:10 |g pages:1152-1170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4143/crt.2023.493 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 4 |b 23 |c 10 |h 1152-1170 | ||